Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Teva's Xgeva Biosimilar Degevma Gets FDA Nod

30 September 2026 · By · Wire by Fusion42

Published

30 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at endocrinologyadvisor.com →

◆ Verified

Fusion42 · 1 October 2026 · Fusion42 review

The FDA has approved Degevma (denosumab-adet), a biosimilar to Xgeva (denosumab), demonstrating bioequivalence in safety, efficacy, and immunogenicity. Degevma is intended for multiple indications related to bone diseases and is expected to be available soon in the US.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Teva's FDA approval for Degevma opens immediate competition for Xgeva buyers, making US bone disease treatment a more contestable market. You can accelerate market entry or partnership talks to capitalise on this new biosimilar option.

◆ Coverage

1 source · 30 Sep 2026

◆ Related on Wire

◆ Topics

BiotechbiosimilarFDA-approvalbiotechbone-healthdenosumab